Quarterly report pursuant to Section 13 or 15(d)

BUSINESS (Details Narrative)

v3.22.2.2
BUSINESS (Details Narrative)
Oct. 31, 2020
Jul. 28, 2016
BioCorRx Pharmaceuticals [Member]    
Equity issued ownership   75.80%
BioCorRx Pharmaceuticals, Inc [Member]    
Management fee 65.00%  
Series B Convertible Preferred Stock    
Equity issued ownership   24.20%